… Between January 2008 and October 2009, we analyzed 125 patients with relapsed
NSCLC who had received erlotinib therapy after gefitinib failure at our institutes. Results were …

… patients were randomly assigned to receive either gefitinib (… Patients were not selected
according to any molecular … , failing to show the hypothesized superiority of gefitinib compared to …

… -refractory NSCLC patients failed to show that gefitinib was … Japan Gefitinib Study Group)
trial compared gefitinib with … treatment in advanced NSCLC patients selected for EGFR mutation…

… Evaluation in Lung cancer), gefitinib failed to prolong survival compared with placebo in …
for predicting response to gefitinib. Appropriate patient selection by clinical characteristics or …

… However, in the present study, high EGFR gene copy number was associated with
objective response to gefitinib but failed to show significant association with prolonged time-to-…

… selected advanced NSCLC patients after failure of gefitinib. Further studies are warranted
to evaluate the molecular mechanisms behind this evidence and clarify how to select patients …

… Platinum-based combination regimens were selected for patients who had a good … date of
failure of the initial gefitinib treatment to the date of death due to any cause. Patients who were …

… to select patients for treatment with gefitinib. This article aims to briefly summarize the profile
of gefitinib, EGFR mutations, landmark trials with gefitinib … However, gefitinib failed to show a …

… timing of withdrawal of gefitinib therapy and the selection of subsequent treatment. New
therapeutic modalities are needed for patients whose tumors have become resistant to gefitinib. …

… who had been treated with gefitinib after failure of prior therapies … as patients who had been
treated with erlotinib after failure of … criteria resulted in the selection of 171 pairs of patients. …